Mechanism of impaired glucose metabolism during nilotinib
therapy in patients with chronic myelogenous leukemia.

J 2013

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

RÁČIL, Zdeněk, Filip RÁZGA, Jana DRÁPALOVÁ, Lucie BUREŠOVÁ, Daniela ŽÁČKOVÁ et. al.

Basic information

Original name

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

Authors

RÁČIL, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Filip RÁZGA (703 Slovakia), Jana DRÁPALOVÁ (203 Czech Republic), Lucie BUREŠOVÁ (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Martina PALACKOVÁ (703 Slovakia, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Ludmila MALÁSKOVÁ (203 Czech Republic), Martin HALUZÍK (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Haematologica, Pavia, ITALY, Ferrata Storti Foundation, 2013, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.868

RIV identification code

RIV/00216224:14740/13:00069041

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.3324/haematol.2013.086355

UT WoS

000328543400001

Keywords in English

Nilotinib; insulin resistance

Abstract

V originále

For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.

Links

ED1.1.00/02.0068, research and development project

Name: CEITEC - central european institute of technology

Files attached

EL_1119840_Mechanism_of_impaired.pdf

Request the author's version of the file

Citovat

RÁČIL, Zdeněk, Filip RÁZGA, Jana DRÁPALOVÁ, Lucie BUREŠOVÁ, Daniela ŽÁČKOVÁ, Martina PALACKOVÁ, Lukáš SEMERÁD, Ludmila MALÁSKOVÁ, Martin HALUZÍK and Jiří MAYER. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. Pavia, ITALY: Ferrata Storti Foundation, 2013, vol. 98, No 10, p. "e124"-"e126", 3 pp. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2013.086355.

@article{1119840,
   author = {Ráčil, Zdeněk and Rázga, Filip and Drápalová, Jana and Burešová, Lucie and Žáčková, Daniela and Palacková, Martina and Semerád, Lukáš and Malásková, Ludmila and Haluzík, Martin and Mayer, Jiří},
   article_location = {Pavia, ITALY},
   article_number = {10},
   doi = {http://dx.doi.org/10.3324/haematol.2013.086355},
   keywords = {Nilotinib; insulin resistance},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica},
   title = {Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.},
   url = {http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1},
   volume = {98},
   year = {2013}
}

TY  - JOUR
ID  - 1119840
AU  - Ráčil, Zdeněk - Rázga, Filip - Drápalová, Jana - Burešová, Lucie - Žáčková, Daniela - Palacková, Martina - Semerád, Lukáš - Malásková, Ludmila - Haluzík, Martin - Mayer, Jiří
PY  - 2013
TI  - Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
JF  - Haematologica
VL  - 98
IS  - 10
SP  - "e124"-"e126"
EP  - "e124"-"e126"
PB  - Ferrata Storti Foundation
SN  - 03906078
KW  - Nilotinib
KW  - insulin resistance
UR  - http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1
L2  - http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1
N2  - For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.
ER  -

RÁČIL, Zdeněk, Filip RÁZGA, Jana DRÁPALOVÁ, Lucie BUREŠOVÁ, Daniela ŽÁČKOVÁ, Martina PALACKOVÁ, Lukáš SEMERÁD, Ludmila MALÁSKOVÁ, Martin HALUZÍK and Jiří MAYER. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. \textit{Haematologica}. Pavia, ITALY: Ferrata Storti Foundation, 2013, vol.~98, No~10, p.~''e124''-''e126'', 3 pp. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2013.086355.

Detailed Information on Publication Record